Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quarterly results round-up: St Jude and Quest cut jobs to rein in costs, Baxter strong again

This article was originally published in Clinica

Executive Summary

Devices were a weak spot in Abbott's second fiscal quarter results. Although sales of its Innovation-Driven Devices (comprising its vascular, ophthalmic and molecular diagnostics businesses) increased 3% to $1.2bn, this was due to a 5% favourable currency effect. On a constant currency basis, sales were down 2%. Within this product segment, vascular devices were mainly blamed for the decline, with revenues down 4%, partly due to the recall of the firm's transcatheter mitral heart valve MitraClip (www.clinica.co.uk, 11 May 2011). However, Abbott claims it has one of the industry's most robust vascular pipelines, including its Absorb bioresorbable stent, which is already available in Europe and looks likely to become the first device of its type to gain US FDA approval, which could come in 2015 (www.clinica.co.uk, 5 April 2011).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel